Concepedia

Eduardo Bullorsky

EB

Statistics

Publications

15

Citations

1.2K

H-Index

12

Active since

1988

Affiliations

Hospital Británico de Buenos Aires(Current)

Experimental Medicine and Biology Institute

Bristol-Myers Squibb (United States)

Cornell University

The University of Texas MD Anderson Cancer Center

Eduardo Bullorsky is an author at Hospital Británico de Buenos Aires specializing in medicine, oncology, and chronic myeloid leukemia therapy.

Publications per year

1988–2016

15

Publications

15

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

François Guilhot, Jane F. Apperley, Dong‐Wook Kim et al. · Blood · 2007 · 372 citations · Full text

, , +14

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia

Hubert Schrezenmeier, Jakob Passweg, Judith Marsh et al. · Blood · 2007 · 291 citations · Full text

, , +15

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Jane F. Apperley, Jörge E. Cortes, Dong‐Wook Kim et al. · Journal of Clinical Oncology · 2009 · 196 citations · Full text

, , +11

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

Michael B. Lilly, Oliver G. Ottmann, Neil P. Shah et al. · American Journal of Hematology · 2009 · 98 citations

, , +12

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala et al. · The Lancet Haematology · 2016 · 40 citations · Full text

, , +9

1–5 of 15